Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically...

Area of Science:

• Pediatric Oncology
• Molecular Biology
• Genetics

Background:

• Medulloblastoma (MB) is a heterogeneous pediatric brain tumor with four main molecular groups.
• These groups are further classified into second-generation MB (SGS MB) subgroups with distinct genetic and clinical features.
• Non-WNT/non-SHH MB (Group 3/4) comprises eight clinically relevant SGS MB subgroups requiring refined risk stratification.

Purpose of the Study:

• To develop an optimal risk stratification for non-WNT/non-SHH medulloblastoma.
• To identify survival-associated genes and pathways specific to SGS MB subgroups.
• To integrate transcriptome data for improved outcome prediction in pediatric MB.

Main Methods:

• DNA- and RNA-based analysis of 574 non-WNT/non-SHH MB samples.
• Multigene analysis to identify survival-associated genes specific to each SGS MB subgroup.
• Development and validation of metagene sets for risk stratification using multivariate models and an independent cohort (n=377).

Main Results:

• Identified numerous survival-associated genes with minimal overlap between non-WNT/non-SHH MB subgroups.
• Discovered subgroup-specific gene expression signatures linked to pathways driving MB diversity and progression.
• Validated subgroup-specific metagene sets as independent predictors of outcome in a separate cohort.

Conclusions:

• Integrating transcriptome data into risk stratification models enhances outcome prediction for non-WNT/non-SHH SGS MB.
• Subgroup-specific gene signatures and metagene sets show potential for clinical implementation in MB risk stratification.
• Further validation in prospective clinical trials is recommended to confirm the prognostic role of these transcriptome-based subtypes.